Dr Reddys Laboratories Faces Reversal Amid Mixed Performance and Sector Underperformance

Dr Reddys Laboratories has experienced a notable decline of 3.08% on March 25, 2025, marking a reversal after seven consecutive days of gains. The stock's performance today underperformed the sector by 2.53%, with an intraday low of Rs 1170.35, reflecting a drop of 3.28%.
In terms of moving averages, the stock is currently above its 20-day moving average but below the 5-day, 50-day, 100-day, and 200-day moving averages, indicating mixed short- to long-term trends. Over the past week, Dr Reddys Laboratories has seen a modest gain of 0.54%, while the broader Sensex index has surged by 4.14%.

Looking at longer-term performance, the stock has faced challenges, with a 3-month decline of 13.34% and a year-to-date drop of 15.65%. In contrast, the Sensex has shown resilience, gaining 0.36% year-to-date. Despite the recent downturn, Dr Reddys Laboratories has demonstrated a 34.26% increase over the past three years, although this lags behind the Sensex's 36.71% growth during the same period.